Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
The companies said the FDA has approved an updated formulation designed to better match the XFG variant, with distribution planned to begin immediately.
THE APEX TIMES
THE APEX TIMES
The approval of nipocalimab-aahu as the first treatment shown for warm autoimmune hemolytic anemia (wAIHA) gives Johnson & Johnson a new, narrowly targeted product in a rare autoimmune category.
THE APEX TIMES
In the first half of 2026, Eli Lilly’s oncology revenues increased 11% year over year, according to a market report that points to traction in newer therapies and contribution from pipeline assets.
THE APEX TIMES
The company said it plans to sell $2 billion in convertible notes, with an option to increase the offering. Traders and retail investors questioned the timing and structure of the deal.
THE APEX TIMES
A new market commentary points to a payout ratio that can look alarming, but argues investors should focus on the underlying earnings or cash-flow pressures behind Pfizer’s dividend.
THE APEX TIMES
A new set of findings highlighted by Yahoo Finance points to a potentially larger weight-loss opportunity for Eli Lilly’s obesity medicines, with implications for payer coverage decisions.
THE APEX TIMES
The company said it will issue $2 billion of notes due in 2032, including an option to raise an additional $300 million, in a financing move announced days after its shares reached a multi-year high.
THE APEX TIMES
The biotech company said it intends to issue $2.0 billion in convertible senior notes in a proposed private offering, subject to market and other conditions.
THE APEX TIMES
The company says the U.S. Food and Drug Administration has approved an autoimmune therapy for a rare blood condition, marking a regulatory milestone for its broader push in specialty immunology.
